Mifegyne (Mifepristone)

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a 200 mg tablet for oral use. It treats medical termination of intrauterine pregnancy up to 9 weeks gestation and is also used in early pregnancy loss, uterine fibroids, and Cushing's syndrome.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifepristone is a progesterone receptor antagonist used in several reproductive and endocrine indications.

- Medical termination of intrauterine pregnancy (up to 9 weeks gestation): induces decidual breakdown and embryo detachment. - Early pregnancy loss: facilitates expulsion of retained products of conception. - Uterine fibroids: reduces fibroid size and associated symptoms. - Cushing's syndrome: lowers cortisol production when combined with glucocorticoid receptor antagonists.

Mifepristone may cause a range of adverse reactions, which are generally categorized as common or serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vaginal bleeding: irregular or heavy bleeding. - Cramping: uterine cramping or abdominal pain. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Heavy hemorrhage: excessive blood loss requiring medical intervention. - Severe infection: signs of sepsis or pelvic infection. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Liver dysfunction: elevated liver enzymes or jaundice.

Mifepristone requires careful clinical assessment before use. - Confirm gestational age: ensure pregnancy is ≤9 weeks before use. - Conduct pre‑treatment evaluation: assess for ectopic pregnancy, anticoagulant use, or uterine abnormalities. - Use in combination therapy: follow with a prostaglandin analogue as recommended. - Monitor for infection: watch for fever, pelvic pain, or foul discharge. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mifepristone can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inducers: such as rifampicin may reduce plasma levels. - Anticoagulants: increased risk of bleeding when combined with warfarin.

Moderate Interactions (Monitor Closely): - Antifungal azoles: may increase mifepristone exposure. - Antihypertensives: potential alteration of blood pressure control. - Hormonal contraceptives: may reduce effectiveness of contraceptive methods.